News & Events

Published On: 10/31/2018

TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B

CHAPEL HILL, NC – October 31, 2018 / PR NEWSWIRE / – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has started enrolling patients in TARGET-HBV.    

TARGET-HBV is an observational study that will conduct a comprehensive review of patients with chronic hepatitis B virus (HBV) infection.  TARGET-HBV plans to enroll up to 5,000 patients across a large network of academic and community sites in the United States to advance the understanding of hepatitis B.

Dr. Anna Lok, TARGET-HBV Scientific Advisor, explained “TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.”

Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited that we have started enrolling patients in our TARGET-HBV community. We have seen significant interest from investigative sites to participate in this important study, and we look forward to continuing to advance the understanding of this challenging disease.” 

About Target RWE

Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.

Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit


Kayla Slake
Marketing Manager

984.234.0268 ext 205